The study was of prodromal and early sufferes, two groups with...

The study was of prodromal and early sufferes, two groups with small populations, all barely showing symptoms in the first place (correct me if i am wrong, i know u will).

Thus it would be very hard to see any cognitive benefits between placebo and those on the drug (of two dosages as well, 100/250mg). This trials sole real purpose was to study plaque reduction.

The only thing good that came out of this study (for share holders) is the decreased brain atrophy (and safety aspects). If real this suggests less brain damage in sufferers, thus one might expect less cognitive decline. It also suggests less oxidants in the brain, so one might assume less soluble beta oligomers creating oxidants which eat away the brain.

This is my understanding in any event. And i think it would be fairly obvious that i am no expert having been relatively burnt financially by the recent results.